Psychedelics company silo pharma working on time-release and dosage ketamine implant and topical, hoping to deliver steady pain relief for four million fibromyalgia sufferers

Englewood cliffs, nj / accesswire / june 23, 2023 / this month, silo pharma (nasdaq:silo) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. the development-stage biopharma company has a portfolio of therapies in its pipeline that merge traditional therapeutics with the latest psychedelic research in its pipeline.
SILO Ratings Summary
SILO Quant Ranking